Evidence suggests that hypo-methylation of promoters of CTCFL (CCCTC-binding factor-like), a member of the cancer-testis antigen family, can be used as a noninvasive biomarker to monitor HCC prognosis [152]. This evidence concerns the gene CTCFL and hepatocellular carcinoma.